Researchers propose consumers buy yearly 'drug licenses' as new way to pay for prescriptions

Changing the way consumers pay for prescription drugs so that the system more closely resembles paying for cell phones or computer software could increase drug use without altering patients’ out-of-pocket spending, health plan costs or drug company profits, according to a new RAND Corporation study.

Researchers propose that consumers pay an annual “license” fee that would entitle them to a year’s worth of medicine for each prescription they take on an ongoing basis, with a very small or no co-payment for each monthly supply.

Such a system could be used to pay for medicines that treat chronic conditions such as high cholesterol, diabetes or asthma without increasing the cost to consumers and may reduce the periods when patients go without such medicines because of the cost, according to a study published in the journal Health Affairs.

“We propose a fundamentally new way for consumers to pay for medicines that are taken for long periods of time to treat chronic health conditions,” said Dana Goldman, corporation chair in health economics and director of the Bing Center for Health Economics at RAND, a nonprofit research organization. “We believe this approach can help improve patient care without costing anyone more money.”

Researchers suggest that a pilot study be organized with the cooperation of health insurers and drug manufacturers to test the benefits of the proposal.

The “two-part pricing” scheme outlined by researchers is used to pay for products in many areas outside the medical world. Payments for Internet service, cable and satellite television, all-you-can-eat buffets and country club memberships are all examples of the pricing plan. Consumers pay a set fee to cover a period of time, with unlimited access to the services. Consumers can use as much or as little as they need.

Maybe the best example of the pricing plan is computer software, researchers say. Instead of paying a fee every time a computer is turned on, consumers pay a one-time fee to buy a license for unlimited use of a company’s computer software operating system, for example.

What makes pharmaceuticals similar to these products -- and different from other health services -- are the very low costs of production and the existence of few good substitutes, researchers say.

The article in Health Affairs outlines how a drug-licensing system might be used to pay for statin drugs -- the most-popular form of prescription medication used to treat high cholesterol.
Researchers examined the current costs of the drugs and how the new pricing plan might affect patient compliance -- whether patients are taking drugs as prescribed by their physicians.

Researchers propose that consumers pay a $195 fee for an annual license for the statin drugs -- equal to what most consumers now pay out of their own pockets each year if they have insurance plans that require $25 per-prescription co-payments. Insurance companies would pay an additional $374 to drug companies for each statin license.

Because there would be no monthly out-of-pocket payments for consumers, researchers suggest that patients would be more likely to take their prescriptions. Analyzing past research about the impact of rising co-payments on patient compliance, researchers suggest the average annual use among patients taking statins would climb from 7.8 months to 9.8 months under the new pricing plan.

The increased use of the medication among patients may result in fewer long-term health problems and lower overall costs to insurance providers, according to the study.

“The up-front cost may discourage some patients from starting drugs, but that could be overcome by allowing monthly payment plans,” Goldman said. “Research suggests that eliminating or greatly reducing co-payments for individual prescriptions will encourage patients to stick with their medicine regimes and that will improve the quality of medical care.”

Spending on prescription drugs has outpaced the growth in total spending on health care in the United States, growing 10 percent from 1998 to 2003 compared to 5 percent growth in all health care costs.

Rising drug costs have caused many insurance plans to increase the co-payments made by consumers, leading to greater concerns about patients skipping medications because of cost. Physicians regularly distribute free samples to patients and some insurance plans have even begun requesting that enrollees engage in pill splitting -- dividing higher-dose tablets to avoid buying additional prescriptions.

Source: RAND Corporation

Related stories:

Govt pays for deadly, unapproved drugs (Update)
(AP) -- Dozens of deaths have been linked to medications that have never been reviewed by the government for safety and effectiveness but are still covered under Medicaid, an Associated Press analysis of federal data has found.
Americans travel abroad for crucial surgery
Before getting two artificial disks to ease the grinding pain in his back, Wayne King asked prospective surgeons where they trained and how many disk replacements they had done. Then he flew to Malaysia for the operation.
Time for a Medicare checkup
Old enough for Medicare but don't know what to buy? Been signed up to the Medicare system for several years but don't know what you really have?
Australia: Call for choice between Medicare or private health cover
Australians should be able to choose either private health cover or Medicare to ensure a more efficient and fair system and help reduce public waiting lists, a health care economist from The Australian National University has proposed.
New consumer research shows that Obama stands to gain from 'Hillary effect'
U.S. Senator Hillary Clinton may do more for U.S. Senator Barack Obama than Ralph Nader did for Al Gore: she could give him an unintended boost. Clinton sought the presidency and then, unlike Nader, exited the race. New research from the University of Minnesota's Carlson School of Management demonstrates that when an option enters and then leaves a market, the most similar remaining option -- in this case Obama -- stands to benefit. Whether it is political candidates or beer, health care plans or automobiles, when one attractive option becomes unavailable, people gravitate toward the most similar remaining option.
Genetic data promises new future for kiwi fruit
Kiwifruit lovers can look forward to new, novel forms of their favourite fruit thanks to the release this week of crucial genetic data which fruit breeders say will help them naturally breed new varieties with increased health properties and exciting colours and flavours.
Members of consumer-driven health plans choosing less care
Consumer-driven health plans (CDHP) -- hailed since their inception in 2000 as a tool to help control costs -- are resulting in members forgoing care and discontinuing drugs to treat chronic medical problems, according to two newly published studies.
Study finds most TV prescription drug ads minimize risk information
Prescription drug ads on television first hit the airwaves just over a decade ago, but a new University of Georgia study finds that most of them still do not present a fair balance of information, especially when it comes to the risk of side effects.

News discussion:

Medicine & Health news